Lai J S M, Tham C C Y, Chua J K H, Poon A S Y, Chan J C H, Lam S W, Lam D S C
United Christian Hospital, Kowloon, Hong Kong, People's Republic of China.
Eye (Lond). 2006 Mar;20(3):309-14. doi: 10.1038/sj.eye.6701867.
To compare the clinical outcome of argon laser peripheral iridoplasty (ALPI) against systemic medications in treatment of acute primary angle-closure (APAC).
Consecutive patients with APAC were recruited and randomized to receive one of two treatment options: immediate ALPI or systemic acetazolamide +/- mannitol. All eyes were followed up for at least 6 months after laser iridotomy. Main outcome measures were intraocular pressure (IOP) and requirement for glaucoma medications.
A total of 41 eyes (39 patients) were randomized into the ALPI group, and 38 eyes (32 patients) into the medical treatment group. There were no significant differences between the two groups in sex, age, presenting IOP, and duration of attack. Mean follow-up duration +/- SD was 15.7 +/- 5.8 months. There were no significant differences between the two groups in mean final IOP and requirement for glaucoma medications.
There were no statistically significant differences in mean IOP and requirement for glaucoma drugs between APAC eyes treated with ALPI and systemic medications.
比较氩激光周边虹膜成形术（ALPI）与全身用药治疗急性原发性闭角型青光眼（APAC）的临床效果。
招募连续的APAC患者并随机分为两种治疗方案之一：立即行ALPI或全身应用乙酰唑胺+/-甘露醇。所有眼睛在激光虹膜切开术后至少随访6个月。主要观察指标为眼压（IOP）和青光眼药物的使用需求。
共41只眼（39例患者）被随机分为ALPI组，38只眼（32例患者）被分为药物治疗组。两组在性别、年龄、初始眼压和发作持续时间方面无显著差异。平均随访时间±标准差为15.7±5.8个月。两组在平均最终眼压和青光眼药物使用需求方面无显著差异。
接受ALPI治疗的APAC眼与接受全身用药治疗的APAC眼在平均眼压和青光眼药物使用需求方面无统计学显著差异。
Zotero 插件